Evidence map›Paper›PMID 33896038›Full record

ArticleJournal of cardiac surgery2021

STratification risk analysis in OPerative management (STOP score) for drug-induced endocarditis.

Andreas Habertheuer, Arnar Geirsson, Thomas Gleason, Joseph Woo, Bryan Whitson, George J Arnaoutakis, Pavan Atluri, Arminder Jassar, Tsuyoshi Kaneko, Arman Kilic and 5 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cardiac surgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 10 institutions in 1 country.

Andreas HabertheuerDepartment of Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID http://orcid.org/0000-0001-7310-8838
Arnar GeirssonDivision of Cardiac Surgery, Yale School of Medicine, New Haven, Connecticut, USA.ORCID http://orcid.org/0000-0002-8943-9962
Thomas GleasonDepartment of Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Joseph WooDepartment of Cardiothoracic Surgery, School of Medicine, Stanford University, California, Stanford, USA.
Bryan WhitsonDivision of Cardiac Surgery, Department of Surgery, Ohio State University Medical Center, Ohio, Columbus, USA.
George J ArnaoutakisDivision of Thoracic and Cardiovascular Surgery, University of Florida, Gainesville, Florida, USA.
Pavan AtluriDivision of Cardiovascular Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Arminder JassarDivision of Cardiothoracic Surgery, Massachusetts General Hospital (MGH), Harvard Medical School, Massachusetts, Boston, USA.
Tsuyoshi KanekoDivision of Cardiac Surgery, Brigham and Women's Hospital, Harvard Medical School, Massachusetts, Boston, USA.
Arman KilicDivision of Cardiac Surgery, Brigham and Women's Hospital, Harvard Medical School, Massachusetts, Boston, USA.ORCID http://orcid.org/0000-0001-8112-8345
Paul C TangDepartment of Cardiac Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA.ORCID https://orcid.org/0000-0003-4211-8587
Asher J SchranzDepartment of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.
Syed Usman Bin MahmoodDivision of Cardiac Surgery, Yale School of Medicine, New Haven, Connecticut, USA.
Makoto MoriDivision of Cardiac Surgery, Yale School of Medicine, New Haven, Connecticut, USA.ORCID http://orcid.org/0000-0002-2367-8354
Ibrahim SultanDepartment of Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID http://orcid.org/0000-0002-1737-4012
Brigham and Women's Hospital · USYale University · USHarvard University · USStanford Medicine · USThe Ohio State University Wexner Medical Center · USUniversity of Florida · USUniversity of Michigan · USUniversity of North Carolina at Chapel Hill · USUniversity of Pennsylvania · USUniversity of Pittsburgh · US

Funding

Targeting Immune-Responsive Gene 1 (Irg1) and Itaconate for Cardioprotection of the Donor Heart for TransplantationR01HL164416 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Paul Tang · 2022 to 2026
$3.3M
Targeting Mineralocorticoid Receptor Condensates to Optimize Donor Heart PreservationR01HL166140 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Paul Tang · 2023 to 2026
$2.7M
NHLBI NIH HHS R01 HL164416NHLBI NIH HHS R01 HL166140
6 · The paper itself

Abstract

backgroundThe opioid epidemic has seen a drastic increase in the incidence of drug-associated infective endocarditis (IE). No clinical tool exists to predict operative morbidity and mortality in patients undergoing surgery.

methodsA multi-institutional database was reviewed between 2011 and 2018. Multivariate logistic regression was fitted in an automated stepwise fashion. The STratification risk analysis in OPerative management of drug-associated IE (STOP) score was constructed. Morbidity was defined as reintubation, prolonged ventilation, pneumonia, renal failure, dialysis, stroke, reoperation for bleeding, and a permanent pacemaker. Cross-validation provided an unbiased estimate of out-of-sample performance.

resultsA total of 1181 patients underwent surgery for drug-associated IE (median age, 39; interquartile range [IQR], 30-54, 386 women [32.7%], 341 reoperations for prosthetic valve endocarditis [28.9%], 316 patients with multivalve disease [26.8%]). Operative morbidity and mortality were 41.1% and 5.9%, respectively. Predictors of morbidity were dialysis (95% confidence interval [CI], 1.16-2.82), emergent intervention (1.83-4.73), multivalve procedure (1.01-1.98), causative organisms other than Streptococcus (1.09-2.02), and type of valve procedure performed [aortic valve procedure (1.07-2.15), mitral valve replacement (1.03-2.05), tricuspid valve replacement (1.21-2.60)]. Predictors of mortality were dialysis (1.29-5.74), active endocarditis (1.32-83), lung disease (1.25-5.43), emergent intervention (1.69-6.60), prosthetic valve endocarditis (1.24-3.69), aortic valve procedure (1.49-5.92) and multivalve disease (1.00-2.95). Variables maximizing explanatory power were translated into a scoring system. Each point increased odds of morbidity and mortality by 22.0% and 22.4% with an accuracy of 94.0% and 94.1%, respectively.

conclusionDrug-related IE is associated with significant morbidity and mortality. An easily-applied risk stratification score may aid in clinical decision-making.

Indexed as

EndocarditisEndocarditis, BacterialHeart Valve ProsthesisPharmaceutical PreparationsAdultFemaleHumansRenal DialysisRetrospective StudiesRisk AssessmentTreatment OutcomePharmaceutical Preparationscardiac surgerydrug useendocarditisvalve surgery

Identifiers

PMID33896038
PMCPMC11179684
OpenAlexW3157314949

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.